Jeff Yass’s Agile Therapeutics AGRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-289
Closed -$3.28K 13985
2022
Q4
$3.28K Buy
+289
New +$3.36K ﹤0.01% 12094
2022
Q3
Sell
-371
Closed -$22K 14539
2022
Q2
$22K Buy
371
+337
+991% +$48.9K ﹤0.01% 12351
2022
Q1
$14K Sell
34
-17
-33% -$10.9K ﹤0.01% 12707
2021
Q4
$50K Buy
51
+5
+11% +$7.05K ﹤0.01% 12548
2021
Q3
$89K Sell
46
-56
-55% -$127K ﹤0.01% 12131
2021
Q2
$272K Buy
102
+29
+40% +$95.6K ﹤0.01% 10992
2021
Q1
$303K Sell
73
-33
-31% -$178K ﹤0.01% 10589
2020
Q4
$609K Buy
106
+18
+20% +$106K ﹤0.01% 7857
2020
Q3
$537K Sell
88
-42
-32% -$241K ﹤0.01% 7516
2020
Q2
$725K Sell
130
-201
-61% -$1.04M ﹤0.01% 6591
2020
Q1
$1.23M Buy
331
+250
+309% +$1.43M ﹤0.01% 4909
2019
Q4
$405K Buy
81
+54
+200% +$189K ﹤0.01% 7403
2019
Q3
$63K Buy
+27
New +$66.5K ﹤0.01% 9719
2018
Q3
Sell
-8
Closed -$8K 10528
2018
Q2
$8K Sell
8
-38
-83% -$133K ﹤0.01% 9473
2018
Q1
$235K Buy
+46
New +$304K ﹤0.01% 8058
2017
Q4
Sell
-8
Closed -$74.5K 10099
2017
Q3
$68K Sell
8
-19
-70% -$146K ﹤0.01% 8467
2017
Q2
$205K Buy
+27
New +$187K ﹤0.01% 8246
2017
Q1
Sell
-11
Closed -$121K 10265
2016
Q4
$121K Buy
+11
New +$154K ﹤0.01% 8987

Other funds holding AGRX

Jeff Yass's AGRX Position: Q1 2023 in Review

Jeff Yass sold out of Agile Therapeutics (AGRX) in Q1 2023, closing a stake of 289 shares — an estimated $3.28K sold.

Jeff Yass first reported a position in AGRX in Q4 2016 and held it in 18 quarters. The position peaked at $1.23M in Q1 2020. 22 funds tracked by Wall St. Rank hold AGRX as of Q1 2023.

  • Jeff Yass reported no remaining Agile Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Jeff Yass sold 289 Agile Therapeutics shares in Q1 2023, an estimated $3.28K.
  • Jeff Yass first reported a position in Agile Therapeutics in Q4 2016 and held it in 18 quarters.
  • Jeff Yass's Agile Therapeutics position peaked at $1.23M in Q1 2020.
  • 22 funds tracked by Wall St. Rank held Agile Therapeutics as of Q1 2023.

Based on Susquehanna International Group's 13F filing for Q1 2023, filed 16 May 2023.